Nasus Pharma Ltd.
NSRX | AMEX
$3.16
-$0.15 (-4.53%)
At close: Oct 30, 2026, 3:59 PM ET
$3.16
$0.00 (0.00%)
After-hours:
Oct 30, 2026, 3:59 PM ET
Fiscal Year Period Ending | FY 2025 Dec 31, 2025 | FY 2024 Dec 31, 2024 | FY 2023 Dec 31, 2023 | FY 2022 Dec 31, 2022 |
|---|---|---|---|---|
Net Income | -5.81M | -1.55M | -1.01M | -2.15M |
Depreciation & Amortization | n/a | n/a | n/a | n/a |
Stock-Based Compensation | 447K | 10K | 39K | 23K |
Other Working Capital | -616K | 410K | 283K | 327K |
Other Non-Cash Items | 904K | 472K | -230K | 441K |
Deferred Income Tax | n/a | n/a | n/a | n/a |
Change in Working Capital | -464K | 405K | 167K | 477K |
Operating Cash Flow | -4.92M | -665K | -1.03M | -1.21M |
Capital Expenditures | -14K | n/a | n/a | n/a |
Cash Acquisitions | n/a | n/a | n/a | n/a |
Purchase of Investments | n/a | n/a | n/a | n/a |
Sales Maturities Of Investments | n/a | n/a | n/a | n/a |
Other Investing Acitivies | -3M | n/a | n/a | -160K |
Investing Cash Flow | -3.01M | n/a | n/a | -160K |
Debt Repayment | 435K | 1M | 1.06M | 1.47M |
Common Stock Repurchased | n/a | n/a | n/a | n/a |
Dividend Paid | n/a | n/a | n/a | n/a |
Other Financial Acitivies | n/a | -230K | n/a | -231K |
Financial Cash Flow | 8.92M | 770K | 1.06M | 1.24M |
Net Cash Flow | 980K | 101K | 39K | -143K |
Free Cash Flow | -4.93M | -665K | -1.03M | -1.21M |
Adj. Free Cash Flow | -5.38M | -675K | -1.07M | -1.23M |
Maintenance CapEx | n/a | n/a | n/a | n/a |
Growth CapEx | -14K | n/a | n/a | n/a |
Owner Earnings | -4.92M | -665K | -1.03M | -1.21M |
Add to Watchlist
Select watchlists to add or remove NSRX